X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs DISHMAN PHARMA - Comparison Results

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA DISHMAN PHARMA ELDER PHARMA/
DISHMAN PHARMA
 
P/E (TTM) x -0.2 25.1 - View Chart
P/BV x 0.1 3.3 3.0% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ELDER PHARMA   DISHMAN PHARMA
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
DISHMAN PHARMA
Mar-16
ELDER PHARMA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs380374 101.5%   
Low Rs188129 145.8%   
Sales per share (Unadj.) Rs491.2197.8 248.3%  
Earnings per share (Unadj.) Rs-3.221.2 -15.0%  
Cash flow per share (Unadj.) Rs14.434.7 41.5%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs376.5179.9 209.3%  
Shares outstanding (eoy) m20.5480.69 25.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.61.3 45.4%   
Avg P/E ratio x-89.311.9 -752.2%  
P/CF ratio (eoy) x19.77.2 272.0%  
Price / Book Value ratio x0.81.4 53.9%  
Dividend payout %09.4 0.0%   
Avg Mkt Cap Rs m5,83320,306 28.7%   
No. of employees `000NA0.8 0.0%   
Total wages/salary Rs m2,1795,355 40.7%   
Avg. sales/employee Rs ThNM19,252.7-  
Avg. wages/employee Rs ThNM6,459.5-  
Avg. net profit/employee Rs ThNM2,064.1-  
INCOME DATA
Net Sales Rs m10,08915,961 63.2%  
Other income Rs m257265 96.7%   
Total revenues Rs m10,34616,226 63.8%   
Gross profit Rs m-7924,103 -19.3%  
Depreciation Rs m3611,091 33.1%   
Interest Rs m2,756944 291.9%   
Profit before tax Rs m-3,6532,334 -156.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m125624 20.1%   
Profit after tax Rs m-651,711 -3.8%  
Gross profit margin %-7.825.7 -30.5%  
Effective tax rate %-3.426.7 -12.8%   
Net profit margin %-0.610.7 -6.0%  
BALANCE SHEET DATA
Current assets Rs m9,24011,018 83.9%   
Current liabilities Rs m9,9989,517 105.1%   
Net working cap to sales %-7.59.4 -79.9%  
Current ratio x0.91.2 79.8%  
Inventory Days Days46110 41.9%  
Debtors Days Days6035 172.1%  
Net fixed assets Rs m10,12416,304 62.1%   
Share capital Rs m206161 127.4%   
"Free" reserves Rs m5,58212,907 43.3%   
Net worth Rs m7,73414,516 53.3%   
Long term debt Rs m4,8894,189 116.7%   
Total assets Rs m22,88229,805 76.8%  
Interest coverage x-0.33.5 -9.4%   
Debt to equity ratio x0.60.3 219.0%  
Sales to assets ratio x0.40.5 82.3%   
Return on assets %11.88.9 132.0%  
Return on equity %-0.811.8 -7.2%  
Return on capital %22.317.5 127.3%  
Exports to sales %3.024.8 12.3%   
Imports to sales %0.43.7 11.4%   
Exports (fob) Rs m3073,956 7.7%   
Imports (cif) Rs m43596 7.2%   
Fx inflow Rs m3074,952 6.2%   
Fx outflow Rs m125697 18.0%   
Net fx Rs m1814,255 4.3%   
CASH FLOW
From Operations Rs m11,7542,786 421.8%  
From Investments Rs m-561-1,529 36.7%  
From Financial Activity Rs m-6,762-941 718.5%  
Net Cashflow Rs m4,432316 1,400.7%  

Share Holding

Indian Promoters % 39.6 61.4 64.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 3.7 202.7%  
FIIs % 16.8 12.7 132.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 22.1 163.3%  
Shareholders   16,479 46,261 35.6%  
Pledged promoter(s) holding % 77.6 35.8 216.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   VENUS REMEDIES  SHASUN PHARMA  PFIZER  J.B.CHEMICALS  ORCHID PHARMA LTD  

Compare ELDER PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Higher; Automobile & PSU Stocks Rise(Closing)

Indian share markets continued to trade well above the dotted line in the afternoon session amid firm international markets.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

'Buy and Hold Forever' Not The Best Investing Style After All(The 5 Minute Wrapup)

Nov 9, 2017

Even Buffett didn't always Buy and Hold forever. A look at Berkshire's 1992 and 2017 portfolios will tell you the story...

Of Falling Real Estate Prices, Dr Arvind Panagariya and the Art of Continuing to Suck Up(Vivek Kaul's Diary)

Nov 13, 2017

Dr Panagariya claims real estate prices have fallen 25 per cent post demonetisation; the official data doesn't show anything like that.

Your Last Chance to Trade ONLY the Best Stocks(Daily Profit Hunter)

Nov 11, 2017

Techno-Funda opportunities are knocking on your door. Are you ready to receive them?

Why I am the Biggest India Equity Bull on Planet Earth!(The Honest Truth)

Nov 16, 2017

If you have a dream, dream big...about the level of BSE 30 index in 2050!

The Day Warren Buffett Lost All His Money(Smart Contrarian)

Nov 15, 2017

Buffett is still using the lessons he learnt that fateful day.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA - DIVIS LABORATORIES COMPARISON

COMPARE ELDER PHARMA WITH

MARKET STATS